Doximity (NASDAQ:DOCS - Get Free Report) had its target price cut by analysts at KeyCorp from $70.00 to $65.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. KeyCorp's price target suggests a potential upside of 18.33% from the company's current price.
Several other brokerages have also recently commented on DOCS. Canaccord Genuity Group restated a "hold" rating and issued a $60.00 price target (up previously from $40.00) on shares of Doximity in a research note on Wednesday, November 13th. Barclays boosted their target price on Doximity from $52.00 to $75.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Mizuho started coverage on Doximity in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $55.00 price target on the stock. Stephens started coverage on Doximity in a research report on Friday, December 20th. They set an "equal weight" rating and a $55.00 price objective for the company. Finally, Evercore ISI upped their target price on shares of Doximity from $34.00 to $45.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 8th. Thirteen investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $53.00.
Get Our Latest Stock Report on Doximity
Doximity Price Performance
Shares of NASDAQ DOCS traded down $0.55 during midday trading on Wednesday, hitting $54.93. The company's stock had a trading volume of 1,323,995 shares, compared to its average volume of 1,381,719. The firm has a market capitalization of $10.25 billion, a price-to-earnings ratio of 63.14, a price-to-earnings-growth ratio of 4.16 and a beta of 1.38. The business's fifty day simple moving average is $52.62 and its two-hundred day simple moving average is $41.32. Doximity has a 1 year low of $22.96 and a 1 year high of $61.75.
Institutional Trading of Doximity
Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC increased its stake in Doximity by 30.5% in the third quarter. FMR LLC now owns 6,837,733 shares of the company's stock valued at $297,920,000 after purchasing an additional 1,598,602 shares during the period. William Blair Investment Management LLC increased its position in Doximity by 15.8% in the 2nd quarter. William Blair Investment Management LLC now owns 6,404,068 shares of the company's stock valued at $179,122,000 after acquiring an additional 873,682 shares during the period. Lord Abbett & CO. LLC acquired a new position in Doximity in the 3rd quarter valued at about $29,453,000. Los Angeles Capital Management LLC raised its stake in Doximity by 6,242.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 650,874 shares of the company's stock valued at $28,359,000 after acquiring an additional 640,612 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Doximity during the 3rd quarter worth approximately $24,691,000. Hedge funds and other institutional investors own 87.19% of the company's stock.
Doximity Company Profile
(
Get Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.